Anthropic expands Claude Science partnership with Novo Nordisk to test AI-driven drug discovery after $400M Coefficient Bio buy
Anthropic, after acquiring Coefficient Bio for $400 million and launching its Claude Science platform and Model Hardware Standard preview, is expanding work with Novo Nordisk to test Claude Science on drug-discovery problems selected by Novo’s scientists. The collaboration scales Anthropic’s push to automate laboratory science and let AI agents operate physical devices such as microscopes.
Google DeepMind, Sapio, Benchling and others pitch AI “co‑scientists” with divergent architectures as market booms since late 2025
Vendors including Google DeepMind, Sapio Sciences, Benchling, OpenAI and others are offering AI "co-scientist" tools for bench researchers, and they are taking different architectural approaches to how large language models interface with laboratory data as the market grows into a multibillion-dollar wave since late 2025.
AI co‑scientist startup CTO discusses 'hypothesis slop,' deterministic code and compressing a century of science into a decade after OpenAI launches GPT‑Rosalind
Frontier AI labs and cloud providers have recently prioritized pharma R&D, exemplified by OpenAI's April launch of GPT-Rosalind and a partnership with Novo Nordisk. The article discusses an AI co‑scientist startup CTO’s perspectives on topics like 'hypothesis slop,' deterministic code, and accelerating a century of scientific progress into a decade.
See all 9 stories, episodes and videos about Ryan Kosai.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
Organizations
See all 6-
Potato CTO, Founder 2026–present, CTO 2023–2026 · current
-
Attunely Founder / CTO 2018–2023 · past
-
Pioneer Square Labs CTO 2015–2018 · past
Education
-
University of Washington B.S., Electrical Engineering · 2003–2007